St. Joseph’s Hospital Joins Forces with Moffitt to Cure Cancer

August 22, 2006

TAMPA, Fla. – The American Cancer Society predicts that more than 97,000 people in Florida will be diagnosed with cancer this year. Florida ranks second in the U.S. for total cancer incidence and mortality, and cancer has surpassed heart disease as the top killer of Americans under age 85.

St. Joseph’s Hospital and the H. Lee Moffitt Cancer Center & Research Institute want to change that.

The two organizations are forming an affiliate relationship that will enhance the delivery of cancer treatment services in the Tampa Bay area.

“Our new relationship with the H. Lee Moffitt Cancer Center and Research Institute will provide St. Joseph’s patients and physicians with many opportunities to participate in new and exciting advances in research and evolving care concepts,” said John Surprenant, director of St. Joseph’s Cancer Institute. “Together, we can learn from one another how best to help cancer patients find healing.”

St. Joseph’s Hospital now joins the Moffitt Affiliate Network, a collaborative team working to enhance the quality and breadth of cancer care services for Florida cancer patients, their families and the community. Total Cancer Care (TCC), a Moffitt concept, offers “the right care, in the right place and at the right time.”

This relationship allows St. Joseph’s Cancer Institute to provide community-based, compassionate cancer care for which it is well known and respected and, at the same time, to keep pace with research and new and emerging therapies and techniques in an increasingly complex delivery model system. Affiliation with Moffitt allows patients to participate in a wide variety of research trials at St. Joseph’s Hospital while maintaining a full continuum of care at a community hospital.  

”We look forward to a greater collegial working relationship with St. Joseph’s,” said Jack Kolosky, Moffitt’s Executive Vice President. “With this affiliation, we have increased the potential to provide access to clinical trials to cancer patients throughout the Bay area by being able to include St. Joseph's patient population.”